blue cross blue shield reverse course on glp 1 A handful of nonprofit and insurers dipped their toes into expanding coverage for blockbuster weight-loss drugs. Then they quickly pulled them back out. It's still early days of Why we are changing coverage
Description
GLP-1 medications prescribing trends from 20182024 reveal shifts in semaglutide and tirzepatide use for type 2 diabetes and obesity.

Muscle preservation

Research guide to cagrilintide (CagriSema) - long-acting amylin analog achieving 20.4% weight loss in combination with semaglutide in REDEFINE Phase 3 trials.

Read my PlushCare weight loss review if you want to use PlushCare for online weight-loss meds
Traveling with a semaglutide injection pen requires understanding TSA liquid rules, cooling strategies, and international customs

These results are a reassuring signal for clinicians and patients alike, especially as GLP-1 RAs become central in managing T2DM and obesity